CN1189560C - 具有精氨酸脱亚氨酶的细菌的用途以及含有该细菌的组合物 - Google Patents

具有精氨酸脱亚氨酶的细菌的用途以及含有该细菌的组合物 Download PDF

Info

Publication number
CN1189560C
CN1189560C CNB988137054A CN98813705A CN1189560C CN 1189560 C CN1189560 C CN 1189560C CN B988137054 A CNB988137054 A CN B988137054A CN 98813705 A CN98813705 A CN 98813705A CN 1189560 C CN1189560 C CN 1189560C
Authority
CN
China
Prior art keywords
lactobacillus
bifidobacterium
pharmaceutical composition
ischemic injury
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB988137054A
Other languages
English (en)
Chinese (zh)
Other versions
CN1284994A (zh
Inventor
C·德希莫恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actial Farmaceutica Ltda
Original Assignee
Mendes SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mendes SRL filed Critical Mendes SRL
Publication of CN1284994A publication Critical patent/CN1284994A/zh
Application granted granted Critical
Publication of CN1189560C publication Critical patent/CN1189560C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/24—Lactobacillus brevis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNB988137054A 1998-02-20 1998-10-13 具有精氨酸脱亚氨酶的细菌的用途以及含有该细菌的组合物 Expired - Lifetime CN1189560C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT98RM000103A IT1298918B1 (it) 1998-02-20 1998-02-20 Uso di batteri dotati di arginina deiminasi per indurre apoptosi e/o ridurre una reazione infiammatoria e composizioni farmaceutiche
ITRM98A000103 1998-02-20

Publications (2)

Publication Number Publication Date
CN1284994A CN1284994A (zh) 2001-02-21
CN1189560C true CN1189560C (zh) 2005-02-16

Family

ID=11405583

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB988137054A Expired - Lifetime CN1189560C (zh) 1998-02-20 1998-10-13 具有精氨酸脱亚氨酶的细菌的用途以及含有该细菌的组合物

Country Status (24)

Country Link
US (2) US6572854B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP1058725B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP4253439B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100594569B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1189560C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (2) AR020053A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE391774T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU754483B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR9815677A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2321263C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (1) CY1108112T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69839351T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK1058725T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA006018B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2303357T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL137799A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (2) IN188450B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IT (1) IT1298918B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX237377B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT1058725E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI1058725T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TR (1) TR200002326T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1999042568A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA9811619B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102433290A (zh) * 2012-01-16 2012-05-02 江南大学 一株产瓜氨酸的菌株及用该菌株生物合成瓜氨酸的方法

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1296148B1 (it) * 1996-11-22 1999-06-09 Renata Maria Anna Ve Cavaliere Uso di batteri lattici per accrescere il livello delle ceramidi della pelle e delle mucose, e composizioni dermatologiche e cosmetiche atte
IT1311495B1 (it) * 1999-06-09 2002-03-13 Mendes S U R L Composizione comprendente sfingomielinasi alcalina, utilizzabile qualeprodotto dietetico, integratore alimentare o medicamento.
US8697051B2 (en) * 1999-06-09 2014-04-15 Vsl Pharmaceuticals Inc. Composition comprising alkaline sphingomyelinase for use as a dietetic preparation, food supplement or pharmaceutical product
IT1306716B1 (it) * 1999-06-21 2001-10-02 Mendes S U R L Associazione di batteri lattici e suo uso per la prevenzione e/o iltrattamento terapeutico di infezioni e di stati infiammatori.
AUPQ415899A0 (en) * 1999-11-19 1999-12-16 Vasse Research Institute Pty Ltd Compositions for and methods of treatment of allergic diseases
HU227086B1 (en) 1999-11-25 2010-06-28 Vakcina Kft Lactobacillus vaccine for treating prostata inflammatory and benign prostata hyperplasia
FR2809312B1 (fr) * 2000-05-25 2002-07-12 Gervais Danone Sa Utilisation de l. casei dans des compositions immunostimulantes
US6767537B2 (en) * 2000-05-26 2004-07-27 Phil Arnold Nicolay Composition and method for the treatment of sinusitis
MXPA04001999A (es) * 2001-09-05 2004-07-16 Vsl Pharmaceuticals Inc Bacterias de acido lactico que comprende dinucleotidos de citosina-guanina no metilados para usarse en terapia.
ITRM20010763A1 (it) * 2001-12-21 2003-06-21 Simone Claudio De Nuovo ceppo di batterio lattico e composizioni commestibili, farmaci e prodotti veterinari che lo contengono.
CN1809378B (zh) * 2002-11-18 2010-06-23 德西涅Rx制药公司 体内抑制病毒复制的方法
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
TW200700074A (en) * 2005-03-04 2007-01-01 Calpis Co Ltd Inducer of t cell apoptosis
CA2607949C (en) 2005-05-31 2012-09-25 Thomas William-Maxwell Boileau Feline probiotic bifidobacteria
CA2609617C (en) 2005-05-31 2014-07-08 The Iams Company Feline probiotic lactobacilli
CA2673235A1 (en) 2006-12-21 2008-06-26 Calpis Co., Ltd. Agents for promoting iga production
CN100584940C (zh) * 2007-05-17 2010-01-27 江南大学 一株产精氨酸脱亚氨酶的菌种及其应用
JP5247120B2 (ja) * 2007-11-02 2013-07-24 雪印メグミルク株式会社 Ｌ−オルニチン含有物の製造方法
EE05341B1 (et) * 2008-05-13 2010-08-16 O� Tervisliku Piima Biotehnoloogiate Arenduskeskus Isoleeritud mikroorganismi tvi Lactobacillus plantarum Inducia DSM 21379 kui organismi loomulikku kaitsev?imet t?stev probiootik, seda sisaldav toiduaine ja kompositsioon ning mikroorganismi kasutamine rakulist immuunsust t?stva ravimi valmistamisek
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
CN101606952B (zh) * 2008-06-17 2012-09-19 上海交通大学医学院附属第三人民医院 乳双歧杆菌在制备预防泌尿系统结石药物中的应用
JP5526320B2 (ja) * 2008-09-04 2014-06-18 国立大学法人旭川医科大学 腸管保護剤
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
CN106890198A (zh) * 2009-10-22 2017-06-27 株式会社益力多本社 癌症发病风险降低剂
JP5660508B2 (ja) * 2010-04-08 2015-01-28 国立大学法人旭川医科大学 腸管保護剤
KR101062779B1 (ko) 2010-04-28 2011-09-06 삼육대학교산학협력단 충치 유발 세균의 성장 억제 활성을 나타내는 비피도박테리움 아돌레센티스 ｓｐｍ1005 균주 및 상기 비피도박테리움 아돌레센티스 ｓｐｍ1005 균주 또는 이의 배양물을 유효 성분으로 하는 충치 예방용 식품 및 약제학 조성물
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
JP2014521602A (ja) 2012-04-04 2014-08-28 ポラリス グループ アルギニンデイミナーゼを用いる処置方法
JP6382934B2 (ja) 2013-03-15 2018-08-29 ポラリス グループ 癌治療のためのａｄｉ−ｐｅｇ２０抗体に対して低減された交差反応性を有するアルギニンデイミナーゼ
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
JP6535285B2 (ja) * 2014-01-22 2019-06-26 株式会社明治 シトルリンの調製方法
SG11201607736UA (en) 2014-03-18 2016-10-28 Tdw Group Engineered chimeric pegylated adi and methods of use
TWI775160B (zh) 2014-09-16 2022-08-21 開曼群島商瑞華藥業集團 用於治療癌症之與adi-peg 20抗體具有降低之交叉反應性的精胺酸脫亞胺酶
SG10201913609PA (en) 2014-12-23 2020-03-30 4D Pharma Res Ltd Immune modulation
SMT201800291T1 (it) 2014-12-23 2018-07-17 4D Pharma Res Limited Polipeptide pirina e modulazione immunitaria
RS59446B1 (sr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Blautia stercosis i wexlerae za upotrebu u lečenju inflamatornih i autoimunskih bolesti
SMT201900539T1 (it) 2015-06-15 2019-11-13 4D Pharma Res Limited Composizioni comprendenti ceppi batterici
EP3360559B1 (en) 2015-06-15 2019-10-23 4D Pharma Research Limited Compositions comprising bacterial strains
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
CA3005781C (en) 2015-11-20 2019-01-22 4D Pharma Research Limited Compositions comprising bacterial strains
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
CN106994134B (zh) * 2016-01-25 2020-08-25 深圳华大生命科学研究院 肠道益生菌在预防和/或治疗糖尿病及其相关疾病中的应用
CA3016179C (en) 2016-03-04 2019-08-13 4D Pharma Plc Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
WO2018009528A1 (en) 2016-07-05 2018-01-11 Tdw Group Combination cancer immunotherapies with arginine depletion agents
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
CN110121340B (zh) 2016-11-02 2023-03-31 波拉里集团 聚乙二醇化精氨酸脱亚氨酶的调配物
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
WO2018125735A1 (en) * 2016-12-29 2018-07-05 Kibow Biotech, Inc. Composition and method for maintaining healthy kidney function
CN108265068B (zh) * 2016-12-31 2021-06-15 江苏众红生物工程创药研究院有限公司 重组精氨酸脱亚胺酶及其产业化制备方法和应用
TW201907929A (zh) 2017-05-22 2019-03-01 英商4D製藥研究有限公司 包含細菌品系之組成物
TW201907931A (zh) 2017-05-24 2019-03-01 英商4D製藥研究有限公司 包含細菌菌株之組合物
LT3638271T (lt) 2017-06-14 2021-01-11 4D Pharma Research Limited Kompozicijos, apimančios bakterines padermes
PL3600363T3 (pl) 2017-06-14 2021-06-14 4D Pharma Research Limited Kompozycje zawierające szczepy bakteryjne
WO2018229236A2 (en) 2017-06-14 2018-12-20 4D Pharma Research Limited Compositions comprising bacterial strains
RU2675110C1 (ru) * 2018-04-09 2018-12-17 Федеральное государственное бюджетное учреждение науки Институт общей генетики им. Н.И. Вавилова Российской академии наук (ИОГЕН РАН) Фармацевтическая композиция для терапии воспалительных заболеваний слизистых оболочек кишечника на основе штамма Lactobacillus brevis 47f, проявляющая местную противовоспалительную активность
FR3082207B1 (fr) * 2018-06-06 2022-03-25 Agronomique Inst Nat Rech Nouvelle souche probiotique de lactobacillus brevis
KR102069622B1 (ko) * 2019-06-25 2020-01-23 한국식품연구원 락토바실러스 퍼멘텀 WiKim0102를 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물
US20230113992A1 (en) * 2020-04-17 2023-04-13 Claudio De Simone Use of bacterial compositions in the treatment and prophylaxis of airway diseases
CN115916230A (zh) * 2020-06-22 2023-04-04 株式会社明治 用于促进白细胞介素-10产生的组合物
KR102363111B1 (ko) * 2021-06-29 2022-02-15 (주)바이오일레븐 항염 및 항산화 활성을 갖는 락토바실러스 퍼멘텀 균주 및 이의 용도
KR102822265B1 (ko) * 2023-02-27 2025-06-19 퓨리셀매니아 주식회사 신규 락토바실러스 브리비스 균주 및 이의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4415550A (en) * 1983-03-04 1983-11-15 Pakhomov Gennady N Treatment-and-prophylactic tooth paste possessing anticarious effect
JP2900279B2 (ja) * 1989-08-02 1999-06-02 株式会社ジャパンエナジー 新規なアルギニンデイミナーゼ、その製造法及び該酵素を有効成分とする制癌剤
US5196195A (en) * 1990-03-27 1993-03-23 Cornell Research Foundation, Inc. Use of arginase to control nitric oxide formation
GB9107305D0 (en) * 1991-04-08 1991-05-22 Unilever Plc Probiotic
AUPM596894A0 (en) * 1994-05-30 1994-06-23 Hybrid Scientific Pty Ltd Composition for treating gastrointestinal disorders - a combination of bismuth salts plus lactobacillus or bifidobacteria species bacteria for treating gastrointestinal disorders
US5599795A (en) * 1994-08-19 1997-02-04 Mccann; Michael Method for treatment of idiopathic inflammatory bowel disease (IIBD)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102433290A (zh) * 2012-01-16 2012-05-02 江南大学 一株产瓜氨酸的菌株及用该菌株生物合成瓜氨酸的方法

Also Published As

Publication number Publication date
KR20010106092A (ko) 2001-11-29
EP1058725A1 (en) 2000-12-13
DE69839351D1 (de) 2008-05-21
AU9644198A (en) 1999-09-06
JP4253439B2 (ja) 2009-04-15
IT1298918B1 (it) 2000-02-07
JP2002504324A (ja) 2002-02-12
ES2303357T3 (es) 2008-08-01
AR020053A1 (es) 2002-04-10
TR200002326T2 (tr) 2000-11-21
EA006018B1 (ru) 2005-08-25
IL137799A (en) 2005-08-31
IN1999KO00116A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2005-03-11
AU754483B2 (en) 2002-11-14
US20030215429A1 (en) 2003-11-20
ATE391774T1 (de) 2008-04-15
HK1033338A1 (en) 2001-08-24
DK1058725T3 (da) 2008-08-18
CY1108112T1 (el) 2014-02-12
CA2321263A1 (en) 1999-08-26
CA2321263C (en) 2009-08-11
US6572854B1 (en) 2003-06-03
KR100594569B1 (ko) 2006-06-30
MXPA00007990A (es) 2001-03-01
WO1999042568A1 (en) 1999-08-26
EP1058725B1 (en) 2008-04-09
ITRM980103A0 (it) 1998-02-20
ITRM980103A1 (it) 1999-08-20
CN1284994A (zh) 2001-02-21
IL137799A0 (en) 2001-10-31
ZA9811619B (en) 1999-06-23
AR071841A2 (es) 2010-07-21
US7147847B2 (en) 2006-12-12
SI1058725T1 (sl) 2008-08-31
DE69839351T2 (de) 2009-06-25
EA200000856A1 (ru) 2001-02-26
MX237377B (es) 2006-05-31
BR9815677A (pt) 2000-10-24
PT1058725E (pt) 2008-06-19
IN188450B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2002-09-28

Similar Documents

Publication Publication Date Title
CN1189560C (zh) 具有精氨酸脱亚氨酶的细菌的用途以及含有该细菌的组合物
KR102448946B1 (ko) 락토바실러스 파라카제이 균주 및 그 용도
EP3536328B1 (en) Food or beverage product, or probiotic composition, comprising lactobacillus johnsonii 456
CN1297653C (zh) 包含戊糖乳杆菌菌株的组合物及其用途
JP5688376B2 (ja) 経口用のｄｎａ損傷修復促進剤及びエラスターゼ活性抑制剤
JP2012040015A (ja) 食養生製品、食品添加物または医薬用アルカリ性スフィンゴミエリナーゼ含有組成物
JP2003501399A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2023523221A (ja) 腸内ビフィズス菌の増殖の刺激
TW202227610A (zh) 食澱粉乳桿菌lam1345分離株及其用途
JP2020137456A (ja) 乳酸菌培養用培地
HK1033338B (en) Use of bacteria endowed with arginine deiminase to induce apoptosis and/or reduce an inflammatory reaction and pharmaceutical or dietetic compositions containing such bacteria
WO2020189228A1 (ja) 腸内有用菌の増殖及び有機酸産生増強剤
EP4631511A1 (en) Probiotic and use thereof
CN115279888B (zh) 具有降低血氨数值效能的菌株及包含其的用于保护神经细胞的组合物
Viswanathan Probiotics Supplements for the Management of Calcium Oxalate Kidney Stones-Are We Ready for it
Starovoitova et al. Probiotic strains with hypocholesterolemic activity as potential basis of functional food products for prevention and concomitant treatment of pathological conditions associated with high cholesterol levels
CN114469990A (zh) 低酰化脂多糖用于抗氧化及预防或治疗疾病的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: ESTELLE PHARM PUR GMBH

Free format text: FORMER OWNER: MENDES S.R.L.

Effective date: 20050513

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20050513

Address after: Portugal Funchal

Patentee after: Actial Farmaceutica Lda.

Address before: Rome Italy

Patentee before: Mendes S.R.L.

C56 Change in the name or address of the patentee
CP02 Change in the address of a patent holder

Address after: Rome Italy

Patentee after: Actial Farmaceutica Lda.

Address before: Portugal Funchal

Patentee before: Actial Farmaceutica Lda.

CX01 Expiry of patent term

Granted publication date: 20050216

CX01 Expiry of patent term